用于膀胱内化疗给药的基于凝胶的纳米载体:体外和体内研究
Gel-Based Nanocarrier for Intravesical Chemotherapy Delivery: In Vitro and In Vivo Study.
作者信息
Chen Ting-Yu, Tsai Ming-Jun, Lin I-Ling, Chang Li-Ching, Wu Pao-Chu
机构信息
School of Pharmacy, College of Pharmacy, Kaohsiung Medical University, Kaohsiung 80708, Taiwan.
Department of Neurology, China Medical University Hospital, Taichung 406040, Taiwan.
出版信息
Pharmaceuticals (Basel). 2020 Oct 22;13(11):329. doi: 10.3390/ph13110329.
Intravesical administration of chemotherapeutic agents can enhance drug accumulation in tumors and reduce systemic side effects. Nanocarriers were developed for intravesical administration and exploit the permeation enhancement effect. In vitro permeation evaluation, the drug transdermal amount and accumulation amounts in the tissue of gemcitabine-loaded nanocarriers through biological membrane significantly increased about 14.833.0-fold and 1.514.1-fold respectively, when compared to a control group of 1% gemcitabine saline solution. In in vivo intravesical administration, the drug accumulation amount in bladder tissue of nanocarrier of 75.2 ± 5.4 μg was revealed as being comparably higher than that of the control group of 44.8 ± 6.4 μg. In confocal laser scanning microscopy imagery, the penetration depth of fluorescent dyes-rhodamine was increased from 80 μm up to 120 μm when a nanocarrier was used. This result implies that the nanocarrier is a promising drug delivery agent for intravesical administration.
膀胱内给药化疗药物可增强肿瘤内药物蓄积并减少全身副作用。已开发出用于膀胱内给药的纳米载体,并利用其渗透增强作用。体外渗透评估显示,与1%吉西他滨盐溶液对照组相比,载有吉西他滨的纳米载体通过生物膜的药物透皮量和在组织中的蓄积量分别显著增加了约14.8至33.0倍和1.5至14.1倍。在体内膀胱内给药中,纳米载体在膀胱组织中的药物蓄积量为75.2±5.4μg,明显高于对照组的44.8±6.4μg。在共聚焦激光扫描显微镜图像中,使用纳米载体时,荧光染料罗丹明的穿透深度从80μm增加到了120μm。这一结果表明,该纳米载体是一种有前景的膀胱内给药药物递送剂。